Antibody Drug Conjugates are monoclonal antibodies that are attached to biologically active drugs by chemical linkers with labile bonds. They combine the unique targeting property of monoclonal antibodies with the cancer cell killing ability of cytotoxic drugs. These allow discrimination between healthy and diseased tissues. Advancements in coupling monoclonal antibodies to cytotoxic drugs permit better control of drug pharmacokinetics, and significantly improve delivery to target tissue. Potent novel anti-cancer drugs can now be used to target cancers, while minimizing the exposure of healthy tissue. The recent approvals of two potent ADCs - ADCETRIS and Kadcyla, followed by several Antibody Drug Conjugates (ADCs) in pipeline highlight the potential for new therapeutic innovations in this industry. According to the RNCOS report entitled "Global Antibody Drug Conjugates Market By Drug (ADCETRIS, Kadcyla), Pipeline Analysis (By Phase, Mode of Action, Linker, Technology, and Indication) Outlook 2022", the ADC market is poised to reach US$ 18.1 Billion by 2022. In this report, there is in-depth market analysis of ADCETRIS and Kadcyla. The market potential of these ADCs is estimated considering that these are being tested in clinical trials for several cancer indications, besides the ones which have already been approved. The depicted ADCs are expected to show their complete market potential soon in the coming years. Furthermore, in this report, we have structured the information regarding ADCs at various stages of clinical development that are under research or in collaboration, and those individually being developed by companies. The pipeline chapter provides in depth analysis of ADCs of companies as well as research organizations by clinical phase, indications for which they are being developed, mode of action, type of linker, drugs, and technology. Additionally, the study provides all-inclusive current analysis of various ADCs in advanced as well as early stages of development. Moreover, our report places an emphasis on the major drivers and challenges, latest trends and developments, as well as strategic collaborations that can impact industry's growth. In the end, the report enlists some of the key players in the ADC market including in-short business overview of each player along with their product and pipeline portfolios, recent developments, and comparative analysis of their strengths and weaknesses. Conclusively, the report will prove to be a complete and comprehensive source of knowledge and analysis for clients and potential investors or debut makers in this industry.
Table of Contents
1. Analyst View 2. Research Methodology 3. Antibody Drug Conjugate (ADC) - An Introduction 4. ADC Market Outlook to 2022 4.1 ADCETRIS 4.1.1 Market Potential 4.1.2 Market Size and Forecast to 2022 4.2 Kadcyla 4.2.1 Market Potential 4.2.2 Market Size and Forecast to 2022 5. ADC Pipeline Analysis 5.1 By Companies 5.1.1 By Clinical Phase 5.1.2 By Indication 5.1.3 By Drug 5.1.4 By Type of Linker 5.1.5 By Mode of Action 5.1.6 By Technology 5.2 By Research Organizations 5.2.1 By Phase 5.2.2 By Indication 5.2.3 By Drug 5.2.4 By Type of Linker 5.2.5 By Mode of Action 6. Drivers and Challenges 6.1 Drivers 6.1.1 Rising Global Cancer Epidemics 6.1.2 Advances in Linking Technologies Re-Instills Hope in ADC 6.1.3 Efforts towards Patent Protection to Drive ADC Market 6.1.4 Increasing Demand for Antibody Drug Conjugates 6.2 Challenges 6.2.1 Production Hurdles and Cost 6.2.2 Inadequacy of Experienced Manufacturers 6.2.3 Regulatory Challenges 7. Major Potential ADCs in Pipeline 7.1 By Companies 7.1.1 Glembatumumab Vedotin Therapeutics /CDX-011 - Celldex 7.1.2 Coltuximab Ravtansine/SAR3419 - ImmunoGen Inc. 7.1.3 Indatuximab Ravtansine/BT-062 - Biotest 7.1.4 Anti-PSMA ADC Therapeutic - Progenics Pharmaceuticals 7.1.5 Polatuzumab Vedotin/RG7596 - Roche Genentech 7.1.6 DMUC-4064A/RG7882 - Roche Genentech 7.1.7 Mirvetuximab Soravtansine/IMGN853 - ImmunoGen Inc. 7.1.8 Anti-guanylyl Cyclase C/Anti-GCC ADC - Takeda Millennium 7.2 By Research 7.2.1 SGM-101 - SurgiMab in Collaboration with Center for Human Drug Research, Netherlands 7.2.2 Panitumumab-IRDye800 - Eben Rosenthal/Stanford University 7.2.3 90Yttrium Ibritumomab Tiuxetan (Zevalin) - Biogen Idec in Collaboration with Soroka University Medical Center 7.2.4 MOC31-PE - Creative Biolabs in Collaboration with Oslo University Hospital 8. Trends and Developments 8.1 ADC at the Forefront of Treating Hematological Malignancies 8.2 ADCs Proving Advantageous for Breast Cancer Patients 9. Strategic Collaborations in the ADC Industry 10. Competitive Assessment 10.1 Seattle Genetics, Inc. 10.2 F. Hoffman-La Roche Ltd. 10.3 ImmunoGen, Inc. 10.4 Bayer AG 10.5 Novartis AG 10.6 Takeda Pharmaceutical Company Limited 10.7 Immunomedics, Inc. 10.8 Agensys, Inc. 10.9 Concortis Biotherapeutics 10.10 NBE-Therapeutics
List of Tables: Table 4-1: Potential Patients for ADCETRIS (2012) Table 4-2: Ongoing Trials for ADCETRIS Table 4-3: Potential Patients for Kadcyla (2012) Table 4-4: Ongoing Trials for Kadcyla Table 5-1: Global - ADC Pipeline of Companies Table 5-2: Global - ADC Pipeline of Research Organization Table 9-1: Strategic Collaborations in the ADC Industry (2014-2016) Table 10-1: Top Companies by ADCs in Pipeline (2016) Table 10-2: Seattle Genetics, Inc. - ADCs in Pipeline Table 10-3: Seattle Genetics, Inc. - Key Financials (Million US$), 2013-2015 Table 10-4: Seattle Genetics, Inc. - Strengths and Weaknesses Table 10-5: F. Hoffman-La Roche Ltd. - ADCs in Pipeline Table 10-6: F. Hoffman-La Roche Ltd. - Key Financials (Million US$), 2013-2015 Table 10-7: F. Hoffman-La Roche Ltd. - Strengths and Weaknesses Table 10-8: ImmunoGen, Inc. - ADCs in Pipeline Table 10-9: ImmunoGen, Inc. - Key Financials (Million US$), 2014-2016 Table 10-10: ImmunoGen, Inc. - Strengths and Weaknesses Table 10-11: Bayer AG - ADCs in Pipeline Table 10-12: Bayer AG - Key Financials (Million US$), 2013-2015 Table 10-13: Bayer AG - Strengths and Weaknesses Table 10-14: Novartis AG - ADCs in Pipeline Table 10-15: Novartis AG - Key Financials (Million US$), 2014-2016 Table 10-16: Novartis International AG - Strengths and Weaknesses Table 10-17: Takeda Pharmaceutical Company Limited - ADCs in Pipeline Table 10-18: Millenium Pharmaceuticals - ADCs in Pipeline Table 10-19: Takeda Pharmaceutical Company Limited - Key Financials (Million US$), 2014-2016 Table 10-20: Immunomedics, Inc. - ADCs in Pipeline Table 10-21: Immunomedics, Inc. - Key Financials (Million US$), 2014-2016 Table 10-22: Agensys, Inc. - ADCs in Pipeline Table 10-23: Astellas Pharma Inc. - Key Financials (Million US$), 2014-2016 Table 10-24: Oxford BioTherapeutics - ADCs in Pipeline Table 10-25: Concortis Biotherapeutics - ADCs in Pipeline Table 10-26: NBE-Therapeutics - ADCs in Pipeline
Our library has over 100000 reports on 1000s of topics
Over 100+ Fortune 500 companies rely on us
90,000+ people come to us for insights every month
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.